NATURAL ALTERNATIVES INTERNATIONAL INC
NAII evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NAII—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Market Cap
$16.8M
Cash Runway
—
Lead Asset
carnosyn
Next Catalyst
—
Financial data as of Mar 31, 2026.
Tracking 3 pipeline candidates for NATURAL ALTERNATIVES INTERNATIONAL INC.
Run NATURAL ALTERNATIVES INTERNATIONAL INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NATURAL ALTERNATIVES INTERNATIONAL INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 1.45
No tracked pipeline phase
3 candidates
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Pipeline
Financials
Short Interest
as of Apr 21, 2026- % of float
- 0.2%
- Days to cover
- 0.4
- Shares short
- 10,701
- Daily short volume (Jun 18, 2026)
- 10.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NAII short interestGovernance
Frequently asked questions
Who is the CEO of NATURAL ALTERNATIVES INTERNATIONAL INC?
Mr. Mark A. LeDoux J.D. is the chief executive officer of NATURAL ALTERNATIVES INTERNATIONAL INC (NAII).
Where is NATURAL ALTERNATIVES INTERNATIONAL INC headquartered?
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) is headquartered in Carlsbad, CA, United States.
What therapeutic areas does NATURAL ALTERNATIVES INTERNATIONAL INC focus on?
NATURAL ALTERNATIVES INTERNATIONAL INC develops therapies across Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.